Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Total Non-Current Liabilities (2016 - 2024)

Aptevo Therapeutics' Total Non-Current Liabilities history spans 10 years, with the latest figure at $10.8 million for Q4 2024.

  • For Q4 2024, Total Non-Current Liabilities fell 14.14% year-over-year to $10.8 million; the TTM value through Dec 2024 reached $10.8 million, down 14.14%, while the annual FY2024 figure was $10.8 million, 14.14% down from the prior year.
  • Total Non-Current Liabilities for Q4 2024 was $10.8 million at Aptevo Therapeutics, up from $10.7 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $55.4 million in Q4 2021 and bottomed at $10.4 million in Q2 2024.
  • The 5-year median for Total Non-Current Liabilities is $12.6 million (2023), against an average of $22.2 million.
  • The largest annual shift saw Total Non-Current Liabilities surged 49.88% in 2021 before it plummeted 70.68% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $37.0 million in 2020, then soared by 49.88% to $55.4 million in 2021, then plummeted by 70.68% to $16.2 million in 2022, then fell by 22.29% to $12.6 million in 2023, then dropped by 14.14% to $10.8 million in 2024.
  • Per Business Quant, the three most recent readings for APVO's Total Non-Current Liabilities are $10.8 million (Q4 2024), $10.7 million (Q3 2024), and $10.4 million (Q2 2024).